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BACKGROUND AND PURPOSE: Stroke is a common cause of death and a leading cause of disability and morbidity. Stroke risk 
assessment remains a challenge, but circulating biomarkers may improve risk prediction. Controversial evidence is available 
on the predictive ability of troponin concentrations and the risk of stroke in the community. Furthermore, reports on the 
predictive value of troponin concentrations for different stroke subtypes are scarce.
METHODS: High-sensitivity cardiac troponin I (hsTnI) concentrations were assessed in 82 881 individuals (median age, 50.7 
years; 49.7% men) free of stroke or myocardial infarction at baseline from 9 prospective European community cohorts. 
We used Cox proportional hazards regression to determine relative risks, followed by measures of discrimination and 
reclassification using 10-fold cross-validation to control for overoptimism. Follow-up was based upon linkage with national 
hospitalization registries and causes of death registries.
RESULTS: Over a median follow-up of 12.7 years, 3033 individuals were diagnosed with incident nonfatal or fatal stroke 
(n=1654 ischemic strokes, n=612 hemorrhagic strokes, and n=767 indeterminate strokes). In multivariable regression 
models, hsTnI concentrations were associated with overall stroke (hazard ratio per 1-SD increase, 1.15 [95% CI, 
1.10–1.21]), ischemic stroke (hazard ratio, 1.14 [95% CI, 1.09–1.21]), and hemorrhagic stroke (hazard ratio, 1.10 
[95% CI, 1.01–1.20]). Adding hsTnI concentrations to classical cardiovascular risk factors (C indices, 0.809, 0.840, 
and 0.736 for overall, ischemic, and hemorrhagic stroke, respectively) increased the C index significantly but modestly. 
In individuals with an intermediate 10-year risk (5%–20%), the net reclassification improvement for overall stroke was 
0.038 (P=0.021).
CONCLUSIONS: Elevated hsTnI concentrations are associated with an increased risk of incident stroke in the community, 
irrespective of stroke subtype. Adding hsTnI concentrations to classical risk factors only modestly improved estimation of 
10-year risk of stroke in the overall cohort but might be of some value in individuals at an intermediate risk.
Key Words: cohort studies ◼ epidemiology ◼ risk assessment ◼ stroke ◼ troponin
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Stroke risk assessment in the community remains a challenge. Although many clinical risk factors for stroke have been identified, a substantial propor-
tion of stroke risk remains unexplained.1 Cardiac tropo-
nin is a structural protein released into the blood flow 
as a consequence of myocardial injury.2 Its usefulness 
as a sensitive marker for myocardial damage has been 
widely tested and become a routine measurement in 
clinical practice, in particular, in the diagnosis of acute 
coronary syndromes.3 However, high-sensitivity assays 
have led to a significantly enhanced detection of tropo-
nin concentrations, considerably broadening its clinical 
application and interpretation.4 Mild elevations of tropo-
nin concentrations are associated with a higher risk for 
cardiovascular disease and death in the general popula-
tion.4–6 A recent meta-analysis showed an association 
between elevated troponin concentrations and incident 
stroke in the general population but also revealed large 
heterogeneity among the included studies.7 While the 
additional benefit of high-sensitivity assayed cardiac 
troponins to predict overall cardiovascular disease 
has been repeatedly demonstrated, their value for the 
prediction of incident stroke in primary prevention is 
unknown.5,6,8,9 Furthermore, reports on the association 
and predictive performance of troponin in relation to 
stroke subtypes are scarce.7,9
Therefore, based on cohorts of the BiomarCaRE (Bio-
markers for Cardiovascular Risk Assessment in Europe) 
consortium,10 our primary goal was to further investigate 
the relationship of high-sensitivity cardiac troponin I 
(hsTnI) with incident stroke in Europe and to examine 
a potential difference in the association of hsTnI with 
ischemic and hemorrhagic stroke. In a second step, we 
aimed to determine the additional predictive value of 
hsTnI beyond classical cardiovascular risk factors.
METHODS
Because of the sensitive nature of the data collected for this 
study, requests to access the dataset from qualified research-
ers trained in human subject confidentiality protocols may be 
sent to the corresponding author.
Study Sample
We pooled participant-level data from 9 community cohorts 
of the BiomarCaRE project with information on hsTnI levels 
and stroke status at baseline and follow-up (http://www.bio-
marcare.eu/), the MONICA Brianza Study, the KORA study 
(Cooperative Health Research in the Region of Augsburg), the 
DanMONICA study, the FINRISK study, the MATISS Rome 
study, the Moli-sani study, the Northern Sweden MONICA 
study, the PRIME (Prospective Epidemiological Study of 
Myocardial Infarction) from Belfast, and the SHHEC (Scottish 
Heart Health Extended Cohort), comprising 86 104 unique 
individuals.10 Each cohort is based on population samples with 
baseline examinations between 1982 and 2010, comprising 
in total 21 subcohorts (please see the Data Supplement for 
details on the enrollment and follow-up procedures of each 
cohort). The study protocol was approved by the local ethics 
review boards of all study centers, and all participants provided 
written informed consent. The protocol adhered to the princi-
ples of the Declaration of Helsinki. The data from the cohorts 
were harmonized in the MONICA Risk, Genetics, Archiving and 
Monograph (MORGAM) Project.11
Individuals with a positive history of stroke or myocardial 
infarction based on self-report or prior physician’s diagnosis 
were excluded from analyses, including individuals in whom 
baseline data indicated coronary heart disease, but separa-
tion between myocardial infarction, angina pectoris, and pos-
sible cardiac revascularization was not possible (n=3223). 
Therefore, 82 881 individuals were included in the analysis.
Follow-Up and Definition of Outcomes
Follow-up was mainly based upon linkage with national 
hospitalization registries and causes of death registries. In 
addition, some cohorts obtained information through direct 
contact to participants or general practitioners and linkage 
to the national medication registries. Follow-up for mortal-
ity was obtained from central death registries. The follow-
up for the different cohorts was completed between 2004 
and 2012.12
Incident strokes and identification of the stroke subtype 
were validated according to MORGAM criteria (for details on 
all outcome classifications, please see https://www.ahajournals.
org/journal/str).
Briefly, a stroke was categorized as an ischemic stroke if at 
least one of the following is present:
• Validation of recent brain infarction by necropsy.
• Circumscribed hypodensity changes of recent origin in 
the brain parenchyma on computed tomography.
• Typical signs of infarct in the brain parenchyma on mag-
netic resonance imaging.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
BiomarCaRE  Biomarkers for Cardiovascular Risk 
Assessment in Europe
HR hazard ratio
hsTnI high-sensitivity cardiac troponin I
ICD International Classification of Diseases
KORA  Cooperative Health Research in the 
Region of Augsburg
LoD limit of detection
MORGAM  MONICA Risk, Genetics, Archiving 
and Monograph
NRI net reclassification improvement
NT-proBNP  N-terminal pro-B-type natriuretic 
peptide
PRIME  Prospective Epidemiological Study of 
Myocardial Infarction
SHHEC  Scottish Heart Health Extended 
Cohort
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An event was also considered as ischemic stroke in the data 
analysis if there was no validation according to MORGAM cri-
teria or validation was not possible due to insufficient data, but 
the routine clinical or death certificate diagnoses indicated 
cerebral infarction (International Classification of Diseases [ICD], 
Eighth Revision, code of 432, 433, or 434; ICD, Ninth Revision, 
code of 433 or 434; or ICD, Tenth Revision, code of I63).
Hemorrhagic stroke was defined as first fatal or nonfatal 
intracerebral or subarachnoid hemorrhage based on MORGAM 
criteria. To be classified as hemorrhagic stroke, at least one of 
the following criteria must be present:
• Validation of recent intracerebral hemorrhage or sub-
arachnoid hemorrhage by necropsy.
• Typical signs of bleeding in the brain parenchyma (intrace-
rebral hemorrhage) or signs of blood in the subarachnoid 
cisterns or in cerebral ventricles (subarachnoid hemor-
rhage) on computed tomography or magnetic resonance 
imaging.
• Bloody cerebrospinal fluid (liquor) in the presence of focal 
neurological signs at onset.
An event was also considered as hemorrhagic stroke in the 
data analysis if there was no validation according to MORGAM 
criteria or validation was not possible due to insufficient data 
but the routine clinical or death certificate diagnoses indicated 
hemorrhagic stroke (ICD, Eighth Revision, code of 430 or 431; 
ICD, Ninth Revision, code of 430 or 431; or ICD, Tenth Revision, 
code of I60 or I61).
Strokes that could be classified neither as ischemic nor 
hemorrhagic were called indeterminate. An incident coronary 
event was defined as a composite end point of any cardiac 
revascularization and acute coronary events including hospi-
talization for unstable angina pectoris. Incident atrial fibrillation 
(AF) was defined by date of the first documentation on ECG 
or assignment of the relevant ICD code (427.4 for ICD, Eighth 
Revision; 427.3 for ICD, Ninth Revision; and I48 for ICD, Tenth 
Revision).
Laboratory Methods
All troponin I levels were measured by an hsTnI assay at 
the central BiomarCaRE laboratory in Hamburg (Abbott 
Diagnostics; ARCHITECT i2000SR). In line with previous 
studies, 1.9 pg/mL was considered the limit of detection 
(LoD).6,8 Observed values below this threshold were included 
for analyses in this study (assay range, 0–50 000 pg/mL). 
The assay supported a 10% coefficient of variation at a con-
centration of 5.2 pg/mL.
Statistical Analyses
Baseline characteristics are expressed as numbers and per-
centages for categorical variables, medians and interquartile 
ranges for continuous variables. To avoid possible problems 
caused by obvious outliers, hsTnI data were winsorized by 
replacing the 3 highest hsTnI values with the fourth highest 
value in each subcohort. We used multiple imputation to handle 
missing data in continuous variables.13 For the dichotomous 
variables, missing values were recoded to zero (no) to avoid 
incompleteness (please see https://www.ahajournals.org/jour-
nal/str for details on the multiple imputation).
Association Analyses
To examine the association of hsTnI with incident stroke, 
we performed Cox proportional hazards regression models 
with overall stroke, ischemic stroke, and hemorrhagic stroke 
as the outcome. Age was used as the time scale. In these 
analyses, hsTnI was log-transformed (logarithm of hsTnI+1). 
We performed incremental adjustment starting with a cohort-
adjusted and sex-stratified model (model 1) and then added 
the variables of the Framingham risk score for estimating the 
10-year risk of cardiovascular events in primary care (body 
mass index, systolic blood pressure, total and high-density 
lipoprotein cholesterol level, antihypertensive medication, 
diabetes mellitus, and daily smoking; model 2).14 This set of 
risk factors was used for all analyses. Adjustment for region 
within studies was performed where available. In a third step, 
we calculated a Cox regression analysis with fatal and non-
fatal coronary event as time-dependent covariates (model 3). 
In a further analysis, we also accounted for incident AF as a 
time-dependent covariate (model 4). In a sensitivity analy-
sis, we excluded individuals with prevalent AF or heart failure 
at baseline. MONICA Brianza, KORA, MATISS, and PRIME 
were excluded from the latter 2 analyses since data on AF 
were not available for these cohorts. Individuals were cen-
sored at the end of follow-up, death, or the time of their event 
in respective analyses.
For categorical analysis, we defined 3 cut points for 
hsTnI at 1.9 pg/mL (LoD) as the lowest cut point and by 
further subdividing individuals with observed hsTnI values 
above the LoD into thirds (resulting in cut points of 2.9 and 
4.8 pg/mL, respectively). P trend was calculated for linear 
increase in log relative hazards with increasing categories. 
Kaplan-Meier curves for incident overall stroke, ischemic 
stroke, and hemorrhagic stroke were produced using cat-
egorized troponin concentrations. The score log-rank test 
was used to test for potential survival difference between 
hsTnI categories. Proportional hazards assumption was 
tested by plotting scaled Schoenfeld residuals against fol-
low-up time for each covariate separately and using χ2 test 
to test for a nonzero slope.
Prediction Analyses
In prediction analyses, 10-year absolute risks were estimated 
by a Weibull curve fitted over age for the baseline hazard and 
adjusted by the linear predictor of the estimated Cox model 
with and without hsTnI. Ten-fold cross-validation was used to 
control for overoptimism. The additional value of hsTnI con-
centrations to the Framingham risk factors was assessed 
by calculating C-index improvement, integrated discrimina-
tion improvement, as well as categorical and continuous net 
reclassification improvement (NRI).15 The risk categories 
used for the categorical NRI analysis were 0% to 5%, 5% 
to 10%, 10% to 20%, and >20%. We further determined the 
clinical NRI, which refers to individuals with an intermediate 
10-year risk of cardiovascular events (5%–20%). For the cal-
culation of C indices and NRI, the follow-up time was cen-
sored at 10 years.
A 2-sided value of P≤0.05 was considered statistically 
significant. All statistical analyses were conducted with R 
statistical software, version 3.6.0 (the R project for statistical 
computing).
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RESULTS
Population Characteristics
Eighty-two thousand eight hundred eighty-one individu-
als were included for analyses in this study, 49.7% being 
men. The median age at baseline was 50.7 (interquartile 
range, 18.0) years (Table 1). The prevalence of diabetes 
mellitus at baseline was 3.9%, 14.8% were treated with 
antihypertensive medication, and about every fourth was 
a daily smoker. Over a median follow-up of 12.7 years, 
3033 (3.7%) individuals were diagnosed with stroke. Of 
these, 1654 (2.0% of the overall cohort) had an ischemic 
stroke, 612 (0.7%) had a hemorrhagic stroke, and stroke 
subtype could not be specified in 767 (0.9%) individuals.
hsTnI Concentrations and Their Association 
With Incident Stroke
The median hsTnI value in the overall cohort was 2.4 
pg/mL (interquartile range, 2.7 pg/mL). Values above 
the LoD were observed in 52 902 (63.8%) individuals. 
HsTnI was associated with a significantly increased risk 
for overall (hazard ratio [HR], 1.15 per 1-SD increase 
[95% CI, 1.10–1.21]; P<0.001), ischemic (HR per 
SD, 1.14 [95% CI, 1.09–1.21]; P<0.001), and hemor-
rhagic stroke (HR per SD, 1.10 [95% CI, 1.01–1.20]; 
P=0.032). The inclusion of incident coronary events and 
AF as time-dependent covariates did not markedly alter 
the results (Table 2). The multivariable adjusted HRs for 
incident stroke increased with increasing hsTnI catego-
ries, and individuals in the highest category had a 42% 
increased risk for overall stroke compared with individu-
als with hsTnI levels below the LoD (HR, 1.42 [95% CI, 
1.24–1.61]; P<0.001; Figure 1). The HRs for ischemic 
and hemorrhagic stroke were 1.45 ([95% CI, 1.22–1.74] 
P<0.001) and 1.39 ([95% CI, 1.07–1.80] P<0.001) 
for individuals in the highest compared with the lowest 
category, respectively. Figure 2 displays survival curves 
according to categories of hsTnI for overall, ischemic, and 
hemorrhagic stroke. The association of hsTnI with inci-
dent overall stroke was observed in all cohorts (Figure 3).
hsTnI Concentrations and Stroke Risk
The Framingham risk factors revealed C indices of 0.809, 
0.840, and 0.736 for overall, ischemic, and hemorrhagic 
stroke, respectively. Adding hsTnI as a continuous vari-
able increased the C indices by 0.003 ([95% CI, 0.001–
0.004] P<0.001) for overall stroke, by 0.002 ([95% CI, 
0.001–0.003] P=0.008) for ischemic stroke, and by 
0.006 ([95% CI, 0.002–0.010] P=0.004) for hemor-
rhagic stroke. The addition of hsTnI as a continuous vari-
able showed a categorical NRI of 0.001 ([95% CI, −0.012 
to 0.014] P=0.893) for overall stroke, 0.010 ([95% CI, 
−0.008 to 0.027] P=0.274) for ischemic stroke, and 
−0.0002 ([95% CI, −0.0004 to −0.00004] P=0.014) 
for hemorrhagic stroke. Focusing on individuals with an 
intermediate 10-year risk (5%–20%), we found a clini-
cal NRI for overall, ischemic, and hemorrhagic stroke of 
0.038 ([95% CI, 0.006–0.070] P=0.021), 0.036 ([95% 
CI, −0.014 to 0.087] P=0.159), and 0.150 ([95% CI, 
0.068–0.232] P<0.001), respectively. Details on all risk 
prediction analyses are provided in Table 3.
DISCUSSION
In our pooled analysis of 9 European community-based 
cohorts, we demonstrate an association of hsTnI con-
centrations with incident stroke, independent of stroke 
subtype. The addition of hsTnI to the variables of the 
Framingham risk score hardly improved stroke risk pre-
diction among all subjects. Focusing on individuals with 
an intermediate 10-year stroke risk revealed a moderate 
improvement in net reclassification for overall stroke, as 
well as for stroke subtypes.
hsTnI as a Stroke Risk Factor
A recent meta-analysis of 12 studies conducted in the 
general population demonstrated an association of 
Table 1. Characteristics of the Study Population
General Characteristics n=82 881
Years of baseline examinations, range in years 1982−2010
Age at baseline examination, y 50.7 (18.0)
Men, n (%) 41 166 (49.7)
Stroke risk factors
 Body mass index, kg/m2 26.2 (5.7)
 Systolic blood pressure, mm Hg 131 (28)
 Total cholesterol, mmol/L 5.7 (1.5)
 High-density lipoprotein cholesterol, mmol/L 1.4 (0.5)
 Antihypertensive medication, n (%) 12 253 (14.8)
 Diabetes mellitus, n (%) 3231 (3.9)
 Daily smoker, n (%) 22 371 (27.0)
 HsTnI ≥1.9 pg/mL, n (%) 52 902 (63.8)
 HsTnI, pg/mL 2.4 (2.7)
End points during follow-up
 Stroke (any type), n (%) 3033 (3.7)
 Ischemic stroke, n (%)* 1654 (2.0)
 Hemorrhagic stroke, n (%)* 612 (0.7)
 Death, n (%) 10 753 (13.0)
Other events during follow-up
 Coronary event, n (%) 6102 (7.4)
 AF, n (%) 2888/62 566† (4.6)
Pooled characteristics of the 9 cohorts are presented as absolute and relative 
frequencies for categorical variables and medians and interquartile ranges for 
continuous variables. AF indicates atrial fibrillation; and hsTnI indicates high-
sensitivity cardiac troponin I.
*n=767 strokes could not be classified as ischemic or hemorrhagic.
†Follow-up information on AF was only available in a limited number of cohorts.
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high-sensitivity assayed troponins and incident stroke.7 
However, the authors reported a great heterogeneity in the 
included studies, and no information on stroke subtype was 
provided. A report from the ARIC study (Atherosclerosis 
Risk in Communities) revealed an association of high-sen-
sitivity assayed troponin T with incident ischemic stroke with 
the highest HRs for cardioembolic stroke but did not show 
a significant association with hemorrhagic stroke, possibly 
due to the small numbers of incident events.9 In a more 
recent analysis, an association of hsTnI with incident isch-
emic stroke of similar strength compared with the present 
study was demonstrated using the same hsTnI assay, but 
they did not report on hemorrhagic stroke.5 In the present 
study, we found an association of hsTnI with ischemic and 
hemorrhagic stroke. A possible explanation for the observed 
association between hsTnI and ischemic stroke is that these 
events might be related to asymptomatic arrhythmias, in par-
ticular, AF.16 Although, in some cases of a (cardio)embolic 
stroke, a secondary hemorrhagic transformation might have 
led to a misclassification of stroke subtype, this concept 
does not sufficiently explain the association of hsTnI with 
hemorrhagic stroke. Hypertension and increasing age con-
stitute major risk factors for both stroke subtypes, but etiol-
ogy and further risk factors differ significantly.1,17 Elevated 
hsTnI values reflect a subclinical manifestation of cardiac 
injury, likely as a consequence of cardiac stress due to the 
presence of cardiovascular risk factors, for example, arterial 
hypertension.18 Therefore, the association of hsTnI with inci-
dent stroke might be an indicator of an underlying systemic 
(vascular) disease, considering the overlap of cardiovascu-
lar and cerebrovascular risk factors.
hsTnI as a Predictor of Stroke
HsTnI hardly improved overall risk prediction beyond 
classical cardiovascular risk factors in this study. Earlier 
Table 2. HRs for hsTnI in Relation to Stroke
Continuous hsTnI* Categorical hsTnI†
No. of EventsHR per SD (95% CI) P Value HR (95% CI) P Value
Overall stroke
 Model 1 1.21 (1.16–1.26) <0.001 1.68 (1.48–1.90) <0.001 3033
 Model 2 1.15 (1.10–1.21) <0.001 1.42 (1.24–1.61) <0.001 3033
 Model 3 1.14 (1.10–1.18) <0.001 1.42 (1.28–1.55) <0.001 2994
 Model 4 1.14 (1.10–1.18) <0.001 1.40 (1.26–1.54) <0.001 2391
Ischemic stroke
 Model 1 1.20 (1.14–1.26) <0.001 1.73 (1.46–2.06) <0.001 1654
 Model 2 1.14 (1.09–1.21) <0.001 1.45 (1.22–1.74) <0.001 1654
 Model 3 1.14 (1.09–1.19) <0.001 1.47 (1.28–1.65) <0.001 1633
 Model 4 1.13 (1.07–1.18) <0.001 1.41 (1.21–1.61) <0.001 1210
Hemorrhagic stroke
 Model 1 1.14 (1.05–1.24) 0.003 1.53 (1.18–1.97) 0.001 612
 Model 2 1.10 (1.01–1.20) 0.032 1.39 (1.07–1.80) 0.013 612
 Model 3 1.10 (1.01–1.18) 0.030 1.39 (1.12–1.66) 0.016 607
 Model 4 1.10 (1.01–1.20) 0.037 1.39 (1.09–1.69) 0.033 496
Model 1: stratified by sex, adjusted for age and cohort. Model 2: adjustment as in model 1 plus adjustment for cardiovascular risk factors at 
baseline (body mass index, systolic blood pressure, total and high-density lipoprotein cholesterol level, antihypertensive medication, diabetes 
mellitus, and daily smoking). Model 3: adjustment as in model 2 plus coronary events as time-dependent variables as these events occurred 
during follow-up. Model 4: adjustment as in model 2 plus AF as further time-dependent variable as it occurred during follow-up (restricted 
number of cohorts). Age was used as the time scale in all models. n=767 strokes could not be classified as ischemic or hemorrhagic. AF 
indicates atrial fibrillation; HR, hazard ratio; hsTnI, high-sensitivity cardiac troponin I; and LoD, limit of detection.
*hsTnI concentrations were log-transformed for this analysis.
†Results presented here are from individuals with hsTnI values in the highest category (hsTnI, ≥4.8 pg/mL) compared with individuals with 
hsTnI values below the LoD (hsTnI, <1.9 pg/mL).
Figure 1. Hazard ratios (HRs) and 95% CIs for high-sensitivity 
cardiac troponin I (hsTnI) categories.  
The presented HRs are based on a sex-stratified Cox regression 
analyses with adjustment for cohort, body mass index, systolic 
blood pressure, total and high-density lipoprotein cholesterol 
level, antihypertensive medication, diabetes mellitus, and daily 
smoking (model 2).
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studies demonstrated a potential benefit in global cardio-
vascular risk prediction by addition of hsTnI, but reports 
focusing on incident stroke are rare.5,6,8 Two prior studies 
found no significant improvement in stroke risk predic-
tion by adding high-sensitivity troponin T or hsTnI.8,9 It is 
difficult to improve discrimination beyond classical risk 
factors, in particular, when risk indicators such as hsTnI 
are partially correlated with the other variables.6,15 In the 
setting of primary prevention, individuals with an esti-
mated intermediate risk for incident disease are most 
likely to benefit from additional guidance on potential 
therapy initiation/modification, since guideline recom-
mendations for these individuals are often less clear.1 
Considering the observed clinical NRI in our study, the 
assessment of hsTnI might be of help in selected indi-
viduals at intermediate cardiovascular risk in whom stan-
dard stroke risk classification yields inconclusive results.
Limitations and Strengths
Several limitations merit consideration. Stroke diagnosis 
was based on medical records rather than on standard 
neurological examination or review of brain imaging. 
Despite the systematic and detailed validation of stroke 
events, residual misclassification cannot be ruled out. 
Furthermore, due to the comparatively small number of 
events, we did not perform separate analyses for sub-
arachnoid and intracerebral hemorrhages, although their 
pathophysiology differs significantly.
HsTnI was measured only once at the time of inclu-
sion of the individuals in the specific cohort. Therefore, 
information on possible changes of hsTnI and how these 
might be related to incident stroke was not available.
Considering that NT-proBNP (N-terminal pro-B-
type natriuretic peptide) has been shown to be asso-
ciated with both ischemic and hemorrhagic stroke,19 it 
would have been preferable to include NT-proBNP into 
our analysis and to assess potential interaction of both 
Figure 2. Kaplan-Meier curves of stroke-free survival according to high-sensitivity cardiac troponin I (hsTnI) categories.  
Numbers below the curves represent individuals at risk for the different hsTnI categories at a certain age. Note that the y axes are truncated at 
0.8. Given P values are for the comparison of the highest and the lowest hsTnI categories.
Figure 3. Hazard ratio (HR) for the highest vs the lowest 
category of high-sensitivity cardiac troponin I (hsTnI) across 
cohorts. 
This figure displays the HRs and 95% CIs (adjusted as in model 2; 
Table 2) for the highest vs the lowest category of hsTnI in the separate 
and overall cohorts for overall stroke. Note that the x axis is truncated 
at 5, since the 95% CI was much wider in 2 cohorts (Moli-sani and 
PRIME [Prospective Epidemiological Study of Myocardial Infarction]). 
KORA indicates Cooperative Health Research in the Region of 
Augsburg; and SHHEC, Scottish Heart Health Extended Cohort.
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biomarkers in their association with incident stroke. How-
ever, NT-proBNP measurements were not available for 
all cohorts, and, therefore, the number of incident stroke 
events would have decreased significantly. Further, ear-
lier studies suggest that the association of troponin with 
stroke is independent of NT-proBNP levels.4,5,9
Our results are based on European cohorts and can-
not be extrapolated to other populations, in particular, 
since an interaction by race for the association of hsTnI 
and stroke has been suggested.5
The strength of our study is the large sample from 
several countries with a long follow-up and carefully har-
monized data in which we can provide results with good 
power, in particular, with regard to the less common out-
come of hemorrhagic stroke.
Conclusions
Elevated hsTnI concentrations are associated with an 
increased risk of incident stroke in the general popula-
tion, irrespective of stroke subtype. A possible explana-
tion may be underlying systemic cardiovascular disease. 
However, adjustment for interim cardiovascular disease 
did not alter the results substantially. Adding hsTnI con-
centrations to classical cardiovascular risk factors only 
modestly improved the prediction of 10-year risk of 
stroke in the overall cohort but might be of some value 
in intermediate-risk groups. More importantly, the patho-
physiological relationship between the cardiac biomarker 
hsTnI and stroke needs to be further elucidated.
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